VivoSeq
Musculoskeletal

Clavicle Fracture

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Clavicle Fracture is an early-stage landscape with 4 programs across 3 companies. The most active players are Fresenius Kabi Oncology Ltd., TLC Biopharmaceuticals, Inc., BOUCHRA BENKESSOU. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fresenius Kabi Oncology Ltd.

1 program

Phase 3T

TLC Biopharmaceuticals, Inc.

1 program

ApprovedB

BOUCHRA BENKESSOU

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Withdrawn2 · 50%
Unknown status1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?
Withdrawn·UUniversity of Minnesota·Phase 4·NCT03020563
Interscalene vs. Superficial Cervical Block vs. Combination for Analgesia After Clavicle Fracture
Unknown status·SSunnybrook Health Sciences Centre·N/A·NCT03094481·120 enrolled
Superficial Cervical Plexus Blockade for Clavicle Fracture Analgesia
Withdrawn·UUniversity of Alabama at Birmingham·Phase 3·NCT03187899
Prospective Study on the Interest of Using an Endobutton Under Fluoroscopic Control Alone to Treat Lateral Quarter Clavicle Fractures and Severe Acromioclavicular Dislocations
Recruiting·BBOUCHRA BENKESSOU·Preclinical·NCT07664202·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)